Patents by Inventor Allen B. Reitz

Allen B. Reitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
    Patent number: 10357497
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole pro drugs useful for the treatment of amyotrophic lateral sclerosis (ALS) and related disorders through the release of riluzole, especially to avoid patient to patient variability in first pass, hepatic metabolism promoted by Cyp 1A2. Pro-drugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process. The invention further includes pro-drugs of riluzole useful for the treatment of disease states that can be treated with riluzole through the release of riluzole from a pro-drug agent.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: July 23, 2019
    Assignee: Biohaven Pharmaceutical Holding Company Limited
    Inventors: Allen B. Reitz, Garry R. Smith
  • ACYL BENZO[D]THIAZOL-2-AMINE AND THEIR METHODS OF USE
    Publication number: 20190209532
    Abstract: Disclosed are acyl benzo[d]thiazol-2-amines having a structure according to formula (I): including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, and complexes thereof. The compounds may be useful for the treatment of various diseases including, for example, neurological disorders such as amyotrophic lateral sclerosis, bipolar disorder, treatment resistant and major depression, general anxiety disorder, and cancers such as melanoma, breast cancer, brain cancer, and prostate cancer.
    Type: Application
    Filed: August 10, 2017
    Publication date: July 11, 2019
    Inventors: Jeffery Claude PELLETIER, Allen B. REITZ, Jay Edward WROBEL
  • ANTIBODY-RECRUITING MOLECULES FOR THE TREATMENT OF CANCER
    Publication number: 20190192497
    Abstract: The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic and other cancers where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells.
    Type: Application
    Filed: August 3, 2017
    Publication date: June 27, 2019
    Inventors: David Spiegel, H. Marie Loughran, Jeffrey C. Pelletier, Allen B. Reitz, Matthew Ernest Welsch
  • Indene derivatives and uses thereof
    Patent number: 10329269
    Abstract: The present invention relates to compounds of formula (I): including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, cancer.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: June 25, 2019
    Assignees: Leukogene Therapeutics Incorporated, MUSC Foundation for Research Development
    Inventors: Nathan G. Dolloff, Reeder M. Robinson, Allen B. Reitz, Haiyan Bian
  • INDENE DERIVATIVES AND USES THEREOF
    Publication number: 20190062298
    Abstract: The present invention relates to compounds of formula (I): including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, cancer.
    Type: Application
    Filed: August 29, 2018
    Publication date: February 28, 2019
    Inventors: Nathan G. Dolloff, Reeder M. Robinson, Allen B. Reitz, Haiyan Bian
  • Antiviral compounds and methods using same
    Patent number: 10160756
    Abstract: The present invention includes compounds that are useful in preventing or treating viral infections, such as viral infections caused by a filovirus, arenavirus, rhabdovirus, paramyxovirus, and/or retrovirus. The present invention further includes compositions comprising such compounds, and methods of treating a viral infection in a subject using such compounds.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: December 25, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Ronald N. Harty, Bruce D. Freedman, Jay E. Wrobel, Allen B. Reitz, H. Marie Loughran
  • Antivirals against molluscum contagiosum virus
    Patent number: 10112895
    Abstract: This invention provides compounds of formulas (I)-(XIV) as defined in the specification, and pharmaceutical compositions comprising the same, and methods of inhibiting, treating, or abrogating a molluscum contagiosum virus infection in a subject using compounds or compositions of the invention:
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: October 30, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Robert P. Ricciardi, Allen B. Reitz, Michael H. Parker, Simon David Peter Baugh, Manunya Nuth, Hancheng Guan
  • EBNA1 INHIBITORS AND METHODS USING SAME
    Publication number: 20180305312
    Abstract: The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
    Type: Application
    Filed: May 14, 2016
    Publication date: October 25, 2018
    Inventors: Troy E. Messick, Garry R. Smith, Allen B. Reitz, Paul M. Lieberman, Mark E. McDonnell, Yan Zhang, Marianne Carlsen, Shuai Chen
  • EBNA1 INHIBITORS AND THEIR METHOD OF USE
    Publication number: 20180086699
    Abstract: Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.
    Type: Application
    Filed: November 16, 2017
    Publication date: March 29, 2018
    Inventors: TROY E. MESSICK, GARRY R. SMITH, ALLEN B. REITZ, PAUL M. LIEBERMAN, MARK E. McDONNELL, YAN ZHANG, VENKATA VELVADAPU
  • PRODRUGS RILUZOLE AND THEIR METHOD OF USE
    Publication number: 20180037557
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Application
    Filed: February 26, 2016
    Publication date: February 8, 2018
    Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffrey Claude Pelletier, Gary Robert Smith, Haiyan Bian
  • RILUZOLE PRODRUGS AND THEIR USE
    Publication number: 20180036290
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Application
    Filed: February 26, 2016
    Publication date: February 8, 2018
    Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffrey Claude Pelletier, Gary Robert Smith, Haiyan Bian
  • EBNA1 inhibitors and their method of use
    Patent number: 9856214
    Abstract: The invention provides EBNA1 inhibitors, and pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The compounds and compositions of the invention are further useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. The compounds and compositions of the invention are further useful for the treatment of diseases caused by lytic EBV infection.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: January 2, 2018
    Assignee: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
    Inventors: Troy E. Messick, Garry R. Smith, Allen B. Reitz, Paul M. Lieberman, Mark E. McDonnell, Yan Zhang, Venkata Velvadapu
  • PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE
    Publication number: 20170334870
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Application
    Filed: August 4, 2017
    Publication date: November 23, 2017
    Inventors: Garry Robert Smith, Allen B. Reitz, Mark Mcdonnell, Suzie Chen, Matthew D. Vera, Benjamin E. Blass, Jeffery Claude Pelletier, Venkata N. Velvadapu, Jay Edward Wrobel
  • Prodrugs of riluzole and their method of use
    Patent number: 9725427
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 8, 2017
    Assignees: Biohaven Pharmaceutical Holding Company Limited, Rutgers, The State University of New Jersey
    Inventors: Garry R. Smith, Allen B. Reitz, Mark McDonnell, Suzie Chen, Matthew D. Vera, Benjamin E. Blass, Jeffery C. Pelletier, Venkata N. Velvadapu, Jay E. Wrobel
  • ANTIVIRALS AGAINST MOLLUSCUM CONTAGIOSUM VIRUS
    Publication number: 20170217882
    Abstract: This invention provides compounds of formulas (I)-(XIV) as defined in the specification, and pharmaceutical compositions comprising the same, and methods of inhibiting, treating, or abrogating a molluscum contagiosum virus infection in a subject using compounds or compositions of the invention:
    Type: Application
    Filed: September 28, 2015
    Publication date: August 3, 2017
    Inventors: Robert P. RICCIARDI, Allen B. REITZ, Michael H. PARKER, Simon David Peter BAUGH
  • NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME
    Publication number: 20170174678
    Abstract: The present invention includes bicyclic compounds that are useful in preventing or treating viral infections, such as viral infections caused by a filovirus, arenavirus, rhabdovirus, paramyxovirus, and/or retrovirus. The present invention further includes compositions comprising such compounds, and methods of treating a viral infection in a subject using such compounds.
    Type: Application
    Filed: March 31, 2015
    Publication date: June 22, 2017
    Inventors: Ronald N. HARTY, Bruce D. FREEDMAN, Jay E. WROBEL, Allen B. REITZ, H. Marie LOUGHRAN
  • NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME
    Publication number: 20170114060
    Abstract: The present invention includes compounds that are useful in preventing or treating viral infections caused by an enveloped RNA virus, such as viral infections caused by a Filovirus, arenavirus, rhabdovirus, paramyxovirus, orthomyxovirus and/or retrovirus. The present invention further includes compositions comprising such compounds, and methods of treating a viral infection in a subject using such compounds.
    Type: Application
    Filed: June 3, 2015
    Publication date: April 27, 2017
    Inventors: Bruce D. FREEDMAN, Ronald N. HARTY, Allen B. REITZ, Jay E. WROBEL
  • EBNA1 INHIBITORS AND THEIR METHOD OF USE
    Publication number: 20160289185
    Abstract: The invention provides EBNA1 inhibitors, and pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The compounds and compositions of the invention are further useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. The compounds and compositions of the invention are further useful for the treatment of diseases caused by lytic EBV infection.
    Type: Application
    Filed: November 14, 2014
    Publication date: October 6, 2016
    Inventors: TROY E. MESSICK, GARRY R. SMITH, ALLEN B. REITZ, PAUL M. LIEBERMAN, MARK E. McDONNELL, YAN ZHANG, VENKATA VELVADAPU
  • TREATMENT OF PROSTATE CANCER AND HEMATOLOGIC NEOPLASMS
    Publication number: 20150209379
    Abstract: Prostate cancer and hematological neoplasms are treated by administration of (i) a compound of Formula I: wherein: R1 is —OH or —O—P(O)(OH)2; and R2 is (II) or (III); (ii) N6-benzyladenosine, (iii) N-(phenylmethyl)-7-?-D-ribofuranosyl-7H-pyrrolo [2,3 -d]pyrimidin-4-amine, (iv) N-(phenylmethyl)-7?-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 5?-monophosphate; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 10, 2013
    Publication date: July 30, 2015
    Applicant: THOMAS JEFFERSON UNIVERSITY
    Inventors: Marja Tuuli Nevalainen, Vincent C. O. Njar, Zhiyong Liao, Allen B. Reitz, Mark E. McDonnell
  • PRO-DRUGS OF RILUZOLE AND THEIR METHOD OF USE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
    Publication number: 20150148329
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole pro drugs useful for the treatment of amyotrophic lateral sclerosis (ALS) and related disorders through the release of riluzole, especially to avoid patient to patient variability in first pass, hepatic metabolism promoted by Cyp 1A2. Pro-drugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process. The invention further includes pro-drugs of riluzole useful for the treatment of disease states that can be treated with riluzole through the release of riluzole from a pro-drug agent.
    Type: Application
    Filed: June 24, 2013
    Publication date: May 28, 2015
    Inventors: Allen B. Reitz, Garry Robert Smith